These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 2850139)

  • 1. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
    Cullmann W
    Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
    Cullmann W; Binder S; Stieglitz M
    Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of YTR 830.
    Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukushima Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1990 Jul; 43(7):1214-24. PubMed ID: 2232151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.
    Coleman K; Griffin DR; Page JW; Upshon PA
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1580-7. PubMed ID: 2817854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.
    Philippon A; Riou JY; Guibourdenche M; Sotolongo F
    Drugs; 1986; 31 Suppl 3():64-9. PubMed ID: 3015547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.